|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
124,070,000 |
Market
Cap: |
147.64(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.5599 - $6.19 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Seres Therapeutics is a microbiome therapeutics platform company developing live biotherapeutic drugs. SER-109, Co.'s lead clinical candidate is an oral, purified bacterial spore-based microbiome therapeutic candidate consisting of a consortium of purified Firmicutes spores. Using Co.'s microbiome therapeutics platform, Co. is also developing SER-287 and SER-301 to treat ulcerative colitis. Co. evaluates microbiome pharmacokinetic and pharmacodynamic data from across its clinical and pre-clinical portfolios using its reverse translation microbiome therapeutics capabilities to conduct research on various indications, including inflammatory and immune diseases, cancer, and metabolic diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
8,738,243 |
Total Buy Value |
$0 |
$0 |
$0 |
$27,525,465 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
36,381 |
36,381 |
71,150 |
83,200 |
Total Sell Value |
$39,292 |
$39,292 |
$86,229 |
$162,501 |
Total People Sold |
7 |
7 |
8 |
8 |
Total Sell Transactions |
7 |
7 |
15 |
17 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Trucksis Michele |
Chief Medical Officer and EVP |
|
2016-07-27 |
4 |
AS |
$35.14 |
$1,337,512 |
D/D |
(38,064) |
0 |
|
- |
|
Trucksis Michele |
Chief Medical Officer and EVP |
|
2016-07-27 |
4 |
OE |
$15.77 |
$600,269 |
D/D |
38,064 |
38,064 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-07-27 |
4 |
AS |
$35.00 |
$700,000 |
D/D |
(20,000) |
183,692 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-07-27 |
4 |
OE |
$0.71 |
$14,200 |
D/D |
20,000 |
203,692 |
|
- |
|
Aunins John G. |
Chief Technology Officer & EVP |
|
2016-07-25 |
4 |
AS |
$34.18 |
$320,950 |
D/D |
(9,390) |
210,765 |
|
- |
|
Aunins John G. |
Chief Technology Officer & EVP |
|
2016-07-22 |
4 |
OE |
$0.48 |
$90,000 |
D/D |
187,500 |
220,155 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-07-06 |
4 |
AS |
$29.27 |
$1,050,716 |
D/D |
(35,435) |
183,692 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-07-06 |
4 |
OE |
$0.71 |
$25,159 |
D/D |
35,435 |
219,127 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-07-05 |
4 |
AS |
$29.27 |
$1,546,758 |
D/D |
(52,776) |
183,692 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-07-05 |
4 |
OE |
$0.71 |
$37,471 |
D/D |
52,776 |
236,468 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-07-01 |
4 |
AS |
$29.12 |
$1,692,705 |
D/D |
(56,789) |
183,692 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-07-01 |
4 |
OE |
$0.71 |
$40,320 |
D/D |
56,789 |
240,481 |
|
- |
|
Shaff Eric D. |
CFO and EVP |
|
2016-06-30 |
4 |
AS |
$29.54 |
$133,905 |
D/D |
(4,533) |
0 |
|
- |
|
Shaff Eric D. |
CFO and EVP |
|
2016-06-30 |
4 |
OE |
$7.79 |
$35,312 |
D/D |
4,533 |
4,533 |
|
- |
|
Shaff Eric D. |
CFO and EVP |
|
2016-06-28 |
4 |
AS |
$28.85 |
$48,093 |
D/D |
(1,667) |
0 |
|
- |
|
Shaff Eric D. |
CFO and EVP |
|
2016-06-28 |
4 |
OE |
$7.79 |
$12,986 |
D/D |
1,667 |
1,667 |
|
- |
|
Shaff Eric D. |
CFO and EVP |
|
2016-06-27 |
4 |
AS |
$28.00 |
$93,352 |
D/D |
(3,334) |
0 |
|
- |
|
Shaff Eric D. |
CFO and EVP |
|
2016-06-27 |
4 |
OE |
$7.79 |
$25,972 |
D/D |
3,334 |
3,334 |
|
- |
|
Aunins John G. |
Chief Technology Officer & EVP |
|
2016-06-27 |
4 |
AS |
$27.23 |
$255,690 |
D/D |
(9,390) |
32,655 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-06-02 |
4 |
AS |
$31.62 |
$2,407,916 |
D/D |
(74,049) |
183,692 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-06-02 |
4 |
OE |
$0.71 |
$52,575 |
D/D |
74,049 |
257,741 |
|
- |
|
Cook David N |
Chief Scientific Officer & EVP |
|
2016-06-02 |
4 |
AS |
$31.00 |
$248,000 |
D/D |
(8,000) |
136,673 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-06-01 |
4 |
AS |
$30.12 |
$2,164,838 |
D/D |
(70,951) |
183,692 |
|
- |
|
Pomerantz Roger |
President and CEO |
|
2016-06-01 |
4 |
OE |
$0.71 |
$50,375 |
D/D |
70,951 |
254,643 |
|
- |
|
Cook David N |
Chief Scientific Officer & EVP |
|
2016-06-01 |
4 |
AS |
$29.43 |
$470,880 |
D/D |
(16,000) |
144,673 |
|
- |
|
195 Records found
|
|
Page 6 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|